Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL. Blood Adv. 2024 Dec 10; 8(23):6139-6147.
PMID: 39093952A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis.
A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis. Blood Adv. 2024 Nov 26; 8(22):5735-5743.
PMID: 39250708Medicaid Coverage Continuity is Associated with Lymphoma Stage among Children and Adolescents/Young Adults.
Medicaid Coverage Continuity is Associated with Lymphoma Stage among Children and Adolescents/Young Adults. Blood Adv. 2024 Nov 12.
PMID: 39531060Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
Venetoclax in combination with a pediatric-inspired regimen for the treatment of newly diagnosed adults with Philadelphia chromosome-negative acute lymphoblastic leukemia. Haematologica. 2024 Nov 07.
PMID: 39506897Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation. Haematologica. 2024 Nov 01; 109(11):3739-3744.
PMID: 38618681Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy. Blood Adv. 2024 10 22; 8(20):5297-5305.
PMID: 39110987Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemia.
Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemia. Innovation (Camb). 2024 Nov 04; 5(6):100719.
PMID: 39529956Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL.
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. J Clin Oncol. 2024 Oct 17; JCO2400321.
PMID: 39418622Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia.
Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemia. Blood. 2024 Oct 07.
PMID: 39374521Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia.
View All Publications
Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia. Nat Genet. 2024 Nov; 56(11):2434-2446.
PMID: 39367245
Wendy Stock, MD
-
Anjuli Seth Nayak Professor of Medicine
Committee on Cancer Biology
Committee on Clinical Pharmacology and Pharmacogenomics - Clinical Interests: Acute Leukemia, Adolescent and Young Adult Cancer Care, CAR TCell Therapy, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Leukemia, Myelodysplastic Syndromes, Stem Cell Transplant Bone Marrow Transplant
- Websites: Research Network Profile
- Contact: wstock@uchicago.edu
- Graduate Programs: Cancer Biology, UChicago Biosciences